Comparative Efficacy and Side Effect Profiles of Interventions for Pediatric Saliva Control: A Cohort Study.

The Journal of pediatrics 2024 Vol.265() p. 113803

Papandreou A, Mahony A, Breaks A, Absoud M, Fairhurst C

관련 도메인

Abstract

[OBJECTIVE] To compare efficacy and side effect profile data on conservative, behavioral, pharmacological, and surgical treatments used for pediatric saliva control.

[STUDY DESIGN] A cohort study of children (n = 483) referred to a specialty Saliva Control service between May 2014 and November 2019 was performed, using quantitative data from pretreatment and post-treatment questionnaires (the Drooling Impact Scale [DIS], Drooling Rating Scale [DRS]) and recording of side effects. Overall, 483 children were included; treatment choices were based on published international guidelines.

[RESULTS] The greatest improvement was seen after intraglandular botulinum toxin A (BTX-A) injections (n = 207; 551 courses; mean DIS change, 34.7; 95% CI = 29.2-35.7) or duct transpositional surgery (n = 31; mean change in DIS, 29.0; 95% CI, 22.3-35.7). Oral anticholinergics were associated with good outcomes, with no significant statistical difference between glycopyrronium bromide (n = 150; mean DIS change, 21.5; 95% CI, 19.1-24.0) or trihexyphenidyl (n = 87; mean DIS change, 22.4; 95% CI, 18.9-25.8). Inhaled ipratropium bromide was not as efficacious (n = 80; mean DIS change, 11.1; 95% CI, 8.9-13.3). Oromotor programs were used in a selected group with reliable outcomes (n = 9; mean DIS change, 13.0). Side effects were consistent with previous studies. Overall, in cases of milder severity, enterally administered therapies provided a good first-line option. With more severe problems, BTX-A injections or saliva duct transpositional surgery were more effective and well tolerated.

[CONCLUSIONS] We describe a large, single-center pediatric saliva control cohort, providing direct comparison of the efficacy and side effect profiles for all available interventions and inform clinical practice for specialists when considering different options. BTX-A injections or saliva duct transpositional surgery seem to be more effective for saliva control that is more severe.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 1
해부 duct scispacy 1
해부 Oral scispacy 1
해부 saliva duct scispacy 1
약물 glycopyrronium bromide C4082411
Glycopyrronium Bromide
scispacy 1
약물 trihexyphenidyl C0041009
trihexyphenidyl
scispacy 1
약물 ipratropium bromide C0700580
ipratropium bromide
scispacy 1
약물 [OBJECTIVE] scispacy 1
약물 BTX-A → botulinum toxin A scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 Drooling C0013132
Drooling
scispacy 1
기타 Saliva scispacy 1
기타 children scispacy 1
기타 intraglandular botulinum toxin A scispacy 1

MeSH Terms

Child; Humans; Saliva; Sialorrhea; Cohort Studies; Botulinum Toxins, Type A; Salivary Ducts; Treatment Outcome; Cerebral Palsy

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문